AAT-730

N/A

Report date: 2025/02/21 14:35:07
NME

Base Information

Drug NameAAT-730
Drug Alias NameAAT-730RQ-00202730OCT-461201
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB2 receptor agonists
TargetsCannabinoid CB2 receptor
Therapy Area/IndicationsDiabetic peripheral neuropathyPainNeuralgia, Postherpetic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Holding France Farevaamboise
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Holding France FarevaamboiseOxford Cannabinoid Technologies LtdOctavian Therapeutics +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetic peripheral neuropathyPainNeuralgia, Postherpetic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A